subscribeSubscribe
price-trendAsk Us
Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder

Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder
BUSINESSWIRE
01 Apr 2024
Share Share
Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray

Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray
PR NEWSWIRE
10 Aug 2023
Share Share
Vistagen stock soars 1,272% on social anxiety spray data

Vistagen stock soars 1,272% on social anxiety spray data
Gabrielle Masson FIERCE BIOTECH
08 Aug 2023
Share Share
Vistagen Announces Positive Results from Phase 3 Trial of Fasedienol

Vistagen Announces Positive Results from Phase 3 Trial of Fasedienol
BUSINESSWIRE
07 Aug 2023
Share Share
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data

Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data
BUSINESSWIRE
01 Jun 2023
Share Share
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data

Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data
BUSINESSWIRE
30 May 2023
Share Share
Anxiety drugs: stressing the importance of innovation

Anxiety drugs: stressing the importance of innovation
PHARMACEUTICAL JOURNAL
04 Jun 2018
Share Share